In contrast, CRP levels increased in patients with GBM (median pre-treatment = 0.1 mg/dl vs. before cycle 2 = 0.195 mg/dl, p = 0.039; Fig. 3c, left panel), while no significant change could be observed in WHO grade II–III glioma (median pre-treatment = 0.06 mg/dl vs. before cycle 2 = 0.13 mg/dl, p = 0.886; Fig. 3c, right panel). Here, CRP is linked to central nervous system cancer.